NASDAQ:CTMX
CytomX Therapeutics Stock News
$2.18
-0.0100 (-0.457%)
At Close: Mar 28, 2024
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
10:25pm, Thursday, 05'th May 2022 Zacks Investment Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
08:15pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
- Patient enrollment completed in Arm A in the Phase 2 study of praluzatamab ravtansine in breast cancer, initial data for both Arms A and B on track for second half of 2022 -
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
12:00pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
08:00am, Thursday, 28'th Apr 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that i
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
08:15pm, Thursday, 14'th Apr 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
08:15pm, Wednesday, 23'rd Mar 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that
CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022
08:00am, Thursday, 17'th Mar 2022
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that p
CytomX Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
07:30pm, Friday, 04'th Mar 2022 Seeking AlphaCytomX stock soars 16% as Q4 revenue rises 20% Y/Y
06:43pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
CytomX Therapeutics <> rose following its FY21 results, which missed on analysts'' estimates.Q4 total revenues rose 20.2% Y/Y to $19.7M. The increase Q4 revenue was largely related…
Organogenesis, CytomX top healthcare gainers; Karyopharm Bright Health lead losers'' pack
03:01pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Gainers: Organogenesis (ORGO) +24%. CytomX Therapeutics (CTMX) +13%. X4 Pharmaceuticals (XFOR) +13%
The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi
12:50pm, Wednesday, 02'nd Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label To Include Advanced Endome
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
CTMX earnings call for the period ending December 31, 2021.
CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript
06:00am, Wednesday, 02'nd Mar 2022 The Motley Fool
CTMX earnings call for the period ending December 31, 2021.
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript
04:38am, Wednesday, 02'nd Mar 2022 Seeking AlphaCytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript
11:38pm, Tuesday, 01'st Mar 2022
CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2021 Results - Earnings Call Transcript